Publish in this journal
Journal Information
Vol. 71. Issue 7.
Pages 584-585 (July 2018)
Download PDF
More article options
Vol. 71. Issue 7.
Pages 584-585 (July 2018)
Scientific letter
Full text access
Triflusal in Patients With Aspirin Hypersensitivity Treated With Coronary Stent Implantation
Triflusal en pacientes con hipersensibilidad al ácido acetilsalicílico tratados con stent coronario
Georgina Fuertes Ferre
Corresponding author

Corresponding author:
, Santiago Laita Monreal, María del Rosario Ortas Nadal, Esther Sánchez Insa, Juan Sánchez Rubio-Lezcano, José Gabriel Galache Osuna
Servicio de Cardiología, Hospital Universitario Miguel Servet, Zaragoza, Spain
Article information
Full Text
Download PDF
Tables (1)
Table. Clinical Characteristics and Adverse Cardiac Events in Patients With a History of Aspirin Hypersensitivity Treated With a Coronary Stent and Dual Antiplatelet Therapy With Triflusal and a Thienopyridine
Full Text
To the Editor,

More and more patients with ischemic heart disease require dual antiplatelet therapy (DAPT).1 In patients undergoing a percutaneous coronary intervention (PCI) and stent implantation, DAPT use lowers the risk of stent thrombosis and adverse cardiac events, but hypersensitivity to aspirin greatly reduces the treatment options. Here, we report the long-term results of a series of patients with aspirin hypersensitivity who underwent coronary stent implantation and were treated with triflusal as an alternative to aspirin.

Between 2000 and 2013 in our center, 68 patients with ischemic heart disease had a history of hypersensitivity reaction to aspirin; 20% of them had undergone aspirin challenge testing. Among the total, 20 patients were treated with a PCI and stent implantation. At the onset of their condition, 17 patients (85%), had an acute coronary syndrome (ACS), 5 of them with ST elevation. Left ventricular systolic function was severely depressed (28%) in 1 patient, and was preserved in the remainder. A summary of the patients’ clinical characteristics is provided in Table.


Clinical Characteristics and Adverse Cardiac Events in Patients With a History of Aspirin Hypersensitivity Treated With a Coronary Stent and Dual Antiplatelet Therapy With Triflusal and a Thienopyridine

Patients, N  20 
Women  11 (55) 
Age, y  68 ± 12 
Smoking  7 (35) 
Diabetes mellitus  5 (25) 
Hypertension  14 (70) 
Dyslipidemia  5 (20) 
Renal failure  2 (1) 
LVEF < 30%  1 (5) 
Peripheral vascular disease  5 (25) 
ACS  17 (85) 
STEACS  5 (25) 
NSTEACS  12 (60) 
Multivessel disease  11 (55) 
No. affected vessels  2 ± 0.7 
Patients with complete revascularization  8 (40) 
No. stents/patient  2 ± 1.4 
Patients treated with drug-eluting stents  10 (50) 
Stent length/lesion, mm  22 ± 6.6 
Adverse events during year 1 
Adverse events from year 1 to 7   
AMI  1 (5) 
Stent thrombosis 
Target lesion revascularization  1 (5) 
Stroke  1 (5) 
CV mortality  1 (5) 
All-cause mortality  7 (35) 

ACS, acute coronary syndrome; AMI, acute myocardial infarction; CV, cardiovascular; LVEF, left ventricular ejection fraction; STEACS, ST-elevation acute coronary syndrome NSTEACS, non–ST-elevation acute coronary syndrome.

Values are expressed as mean ± standard deviation or No. (%), unless otherwise indicated.

Half the patients received a drug-eluting stent. Patients were prescribed DAPT with triflusal 300 mg/12 h and 1 thienopyridine agent (clopidogrel, except in 3 patients with ACS and ST elevation, treated with prasugrel). None of the patients had a hypersensitivity reaction following triflusal administration. The duration of DAPT was 1 year in 18 patients (90%), 2 months in 1 patient with unstable angina treated with a conventional stent, and 6 months in 1 patient with concomitant oral anticoagulation treatment. Following completion of the DAPT period, 75% of patients continued treatment with triflusal indefinitely.

In the first year after the PCI, there were no cases of stent thrombosis or other adverse events. Mortality was 35% (7 patients) after a median follow-up period of 7.1 years. Only 1 patient died due to a cardiovascular cause: sudden death at 6 years following the intervention (Table).

There were no major bleeding events over the entire follow-up period. At more than 1 year following the PCI, 3 patients had experienced minor bleeding episodes (1 rectal bleeding and 2 hematuria).

In patients with aspirin hypersensitivity and ischemic heart disease requiring DAPT, aspirin desensitization is the solution recommended by most professionals. To date, several protocols described for this purpose have included ACS patients treated by stent placement.2 Nonetheless, aspirin desensitization may not always be possible: lack of resources at certain times (it must be done in an intensive care unit), clinically unstable patient, ongoing acute hypersensitivity reaction (asthmatic or angioedema), or a recent anaphylactic reaction.

Triflusal is a drug of the salicylate family that possesses a trifluoromethyl group, a characteristic that differentiates it from aspirin. In contrast to aspirin, triflusal inhibits cyclic adenosine monophosphate phosphodiesterase (cAMP) and cyclic guanosine monophosphate (cGMP). It is as effective as aspirin for inhibiting platelet cyclooxygenase 1 (COX-1), but it is able to maintain endothelial COX-2 expression levels.3 Triflusal has been mainly investigated in relation to peripheral vasculopathy or cerebrovascular disease; to date, the published results in cardiovascular disease are limited. In 1 multicenter study including more than 2000 patients, triflusal was not inferior to aspirin with regard to mortality, reinfarction, or the need for repeat revascularization in acute myocardial infarction patients.4 Furthermore, even though it is a member of the salicylate family, triflusal has proven to be safe for patients with aspirin hypersensitivity leading to exacerbation of respiratory disease.5 In a recent study including 127 patients with a history of aspirin intolerance or hypersensitivity, 8 patients (6.3%) were treated with triflusal and 1 with thienopyridine following implantation of a coronary stent. There were no cases of stent thrombosis during the time patients were receiving DAPT, and the infarction and mortality rate at 3 years of follow-up was 3.1%.6

In the present series of patients with aspirin hypersensitivity treated with a coronary stent, triflusal use was associated with low rate of adverse events at long term, and there were no cases of stent thrombosis in the first year or hypersensitivity reactions to triflusal.

The main limitation of this study is the small number of patients included. In addition, aspirin challenge testing to confirm hypersensitivity was carried out in only 20% of patients, a limitation related to the retrospective nature of the study.

The association of aspirin hypersensitivity and ischemic heart disease requiring DAPT is not common in our daily practice, but it could pose a problem for adequate treatment. If aspirin desensitization cannot be carried out, triflusal use seems to be a safe and effective alternative.

J. Marrugat, R. Elosua, M. Grau, S. Sayols-Baixeras, I.R. Dégano.
Prevalencia y pronóstico de los pacientes con infarto de miocardio de alto riesgo candidatos a doble tratamiento antiagregante prolongado.
Rev Esp Cardiol., 69 (2016), pp. 471-473
B. Vega Hernández, R. Bangueses Quintana, B. Samaniego Lampón, Í. Lozano Martínez-Luengas, G. Gala Ortiz, E. Segovia Martínez de Salinas.
Desensibilización rápida al ácido acetilsalicílico de pacientes con cardiopatía isquémica: experiencia de un centro.
Rev Esp Cardiol., 69 (2016), pp. 795-797
L. Badimon, G. Vilahur.
Mecanismos de acción de los diferentes agentes antiplaquetarios.
Rev Esp Cardiol Supl., 13 (2013), pp. 8-15
J.M. Cruz-Fernández, L. López-Bescós, D. García-Dorado, et al.
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Eur Heart J., 21 (2000), pp. 457-465
J. Fraj, A. Valero, R. Vives, et al.
Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
A. Latib, A. Ielasi, L. Ferri, et al.
Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen.
Int J Cardiol., 165 (2013), pp. 444-447
Copyright © 2017. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?